SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (816)9/17/1997 12:01:00 PM
From: D.Right   of 2173
 
Dear Henry: I gave my view about the potential off-label use of the potential cancer drug from LGND in post #641 on this thread. You responded to that post, too. Somehow, your memery is quite selective. I will repeat my points here. The company (LGND) knows that an off-label use is not something they can depend on, that is why they have to find a rich partner to develop it for the diabetic use. Otherwise, why bother even to try to develop it further, they can just sell it themself off-label. It is pretty hard to sign a partner on good term based on data of animal test only, let along off-label use in the future.

I will stop discussing LGND issues on this thread with you. I hope you understand why. If you have new points not repeated ones, I will discuss it with you on the LGND thread.

Good luck.

D.Right
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News